NCT06841315View on ClinicalTrials.gov

A Varegacestat Hepatic Impairment Study

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

March 7, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

December 31, 2025

Conditions

Healthy VolunteerHepatic Impairment (HI)

Interventions

DRUG

varegacestat

experimental intervention

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

78215

The Texas Liver Institute, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Immunome, Inc.

INDUSTRY

NCT06841315 - A Varegacestat Hepatic Impairment Study | Biotech Hunter | Biotech Hunter